Exact Sciences recently announced its third quarter numbers, which included revenue of $118.3 million and 240,000 completed Cologuard tests, an increase of 63 percent and 49 percent, respectively.

“The Exact Sciences team delivered another strong quarter, highlighted by significantly increased patient access to Cologuard with no out-of-pocket cost and continued progress toward our 2018 priorities,” Exact Sciences CEO Kevin Conroy said in a statement.

According to a release, Exact Sciences anticipates 2018 revenues between $435 million and $440 million.

To date, the company now has in-network contracts with all five top commercial health plans.